Synthesis and evaluation of 2′-substituted 4-(4′-carboxy- or 4′-carboxymethylbenzylidene)-N-acylpiperidines: Highly potent and in vivo active steroid 5α-reductase type 2 inhibitors

Journal of Medicinal Chemistry

Volumn 45, Issue 16, 2002, Pages 3406-3417

  Picard, Franck ^a   Barassin, Stephan ^b   Mokhtarian, Armand ^b   Hartmann, Rolf W ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b Pharmacelsus CRO   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLIDENE DERIVATIVE; FINASTERIDE; ISOENZYME; N (DICYCLOHEXYL)ACETYLPIPERIDINE 4 (2 FLUOROBENZYLIDENE 4 CARBOXYLIC ACID); N (DICYCLOHEXYL)ACETYLPIPERIDINE 4 (BENZYLIDENE 4 ACETIC ACID); PIPERIDINE DERIVATIVE; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CASTRATION; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; FLUORINATION; HUMAN; HUMAN CELL; IC 50; MALE; NONHUMAN; PROSTATE; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; BENZOIC ACIDS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME INHIBITORS; HUMANS; ISOENZYMES; MALE; MODELS, MOLECULAR; ORCHIECTOMY; ORGAN SIZE; PIPERIDINES; PROSTATE; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; TESTOSTERONE; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0036682372     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0208471     Document Type: Article

References (40)

1. Medicinal therapy for benign prostatic hyperplasia
2. A nationwide survey of practicing urologists: Current management of benign prostatic hyperplasia and clinically localized prostate cancer
3. Management of benign prostatic hyperplasia
4. Tissue content of dihydrotestosterone in human prostatic hyperplasia is not supranormal
5. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia
6. Erectile dysfunction following treatments of benign prostatic hyperplasia: A prospective study
7. 4-(1-Benzoylindol-3-yl)butyric acids and FK143: Novel nonsteroidal inhibitors of 5α-reductase (II)
8. Synthesis and biological evaluation of 4-(4-(alkyl- and phenylaminocarbonyl)-benzoyl)benzoic acid derivatives as nonsteroidal inhibitors of steroid-5α-reductase isozymes 1 and 2
9. Synthesis and evaluation of novel steroidal oxime inhibitors of P450 17 (17α-hydroxylase/C17-20-lyase) and 5α-reductases types 1 and 2
10. 6-Substituted 1H-quinolin-2-ones and 2-methoxyquinolines: Synthesis and evaluation as inhibitors of steroid 5α-reductases types 1 and 2
11. New nonsteroidal steroid 5α-reductase inhibitors. Syntheses and structure-activity studies on carboxamide phenylalkyl-substituted pyridones and piperidones
12. N-Substituted 4-(5-indolyl)benzoic acids. Synthesis and evaluation of steroid 5α-reductase type I and II inhibitory activity
13. Synthesis and biochemical evaluation of (carbamoylalkenyl)phenyloxy carboxylic acid derivatives as non-steroidal 5α-reductase inhibitors
14. Novel 5α-reductase inhibitors. Synthesis and structure-activity studies of 5-substituted 1-methyl-2-pyridones and 1-methyl-2-piperidones
15. Synthesis of N-substituted piperidine-4-(benzylidene-4-carboxylic acids) and evaluation as inhibitors of steroid-5α-reductase type 1 and 2
16. 5-Phenyl substituted 1-methyl-2-pyridones and 4′-substituted biphenyl-4-carboxylic acids. Synthesis and evaluation as inhibitors of steroid-5α-reductase type 1 and 2
17. N-Substituted 4-(4-carboxyphenoxy)benzamides. Synthesis and evaluation as inhibitors of steroid-5α-reductase type 1 and 2
18. The effect of carboxyl groups in neighboring side chains on the hydrolysis of substituted benzyl and fluorenyl bromides
19. 1 receptor antagonists
20. New nonpeptide angiotensin II receptor antagonists. 1. Synthesis, biological properties, and structure-activity relationships of 2-alkyl benzimidazole derivatives
21. 4-Aminoquinolines: Novel nociceptin antagonists with analgesic activity
22. Tetrahydro-isoquinoline-based factor Xa inhibitors
23. The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products
24. A mild method for preparing trans-alkenes; crown ether catalysis of the Wittig reaction
25. Novel syntheses of monosubstituted acetic, α,β-unsaturated, and β,γ-unsaturated acids via silylation, hydroboration, and oxidation of the ethynyl group of 1-alkynes and functionally substituted 1-alkynes
26. Species differences in prostatic steroid 5α-reductases of rat, dog, and human
27. Inhibition of the activity of "basic" 5 alpha-reductase (type 1) detected in DU 145 cells and expressed in insect cells
28. Characterization of type 15 alpha-reductase activity in DU145 human prostatic adenocarcinoma cells
29. 5α-reductase in intact DU 145 cells: Evidence for isozyme I and evaluation of novel inhibitors
30. 19-Nor-10-azasteroids: A novel class of inhibitors for human steroid 5α-reductases 1 and 2
31. A novel class of inhibitors for human steroid 5α-reductase: Phenoxybenzoic acid derivatives. I
32. Synthesis and evaluation of 3-carboxymethyl steroids as inhibitors of human prostatic steroid 5α-reductases
33. Inhibition of steroid 5α-reductase by unsaturated 3-nitrosteroids: Synthesis, mechanism of inhibition, and in vivo activity
34. Benzophenone and indolecarboxylic acids: Potent type 2 specific inhibitors of human steroid 5α-reductase
35. Novel lead generation through hypothetical pharmacophore three-dimensional database searching: Discovery of isoflavonoids as nonsteroidal inhibitors of rat 5α-reductase
36. 2 receptors
37. Synthesis of azobis(formamidoacetic acid) and some of its derivatives
38. Quantitation of six androgens by combined high performance liquid chromatography and radioimmunoassay
39. CGP 53153: A new potent inhibitor of 5α-reductase